Panelists discuss how switching from intravenous (IV) to subcutaneous (SubQ) therapies requires proactive management of reimbursement, authorizations, and clinical workflows—emphasizing early payer ...
Despite the benefits and accessibility of administering cancer medications and fluids subcutaneously vs. intravenously, U.S. facilities appear to underuse this delivery method, according to a research ...
ORLANDO, Fla.--(BUSINESS WIRE)-- Millennium: The Takeda Oncology Company today reported results from a randomized, international Phase III clinical trial comparing subcutaneous and intravenous ...
Subcutaneous (SC) administration of medication and fluids for end-of-life cancer care is underutilized in the United States, despite this route having advantages over intravenous (IV) administration, ...
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium Subcutaneous amivantamab-lazertinib demonstrated noninferior ...
The subcutaneous formulation of Opdivo Qvantig reduces administration time to three to five minutes, compared to 30 minutes for the IV version. This formulation offers increased convenience, ...
RESEARCH TRIANGLE PARK, N.C., Oct. 14 /PRNewswire-FirstCall/ -- Talecris Biotherapeutics (Nasdaq: TLCR) announced today that the U.S. Food and Drug Administration ...
Rural local health districts in New South Wales have rolled out a fluid and infusion management solution developed by eHealth NSW. The implementation covers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback